Hjem › Steatotisk leversykdom › Texas
Kliniske studier for Steatotisk leversykdom i Texas
20 studier for Steatotisk leversykdom søker deltakere på steder i Texas.
Byer i Texas
- San Antonio17 studier
- Houston13 studier
- Austin13 studier
- Dallas9 studier
- Brownsville7 studier
- Round Rock7 studier
- Sugar Land6 studier
- Fort Worth6 studier
- Arlington6 studier
- Waco6 studier
- Grand Prairie5 studier
- Pasadena4 studier
- Edinburg4 studier
- Carrollton4 studier
- The Woodlands4 studier
- Lewisville3 studier
- League City3 studier
- Corpus Christi3 studier
Offisiell studietekst (engelsk)
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Arlington
- GSK Investigational Site, Austin
- GSK Investigational Site, Bellaire
- og 5 flere
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07704892A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Arlington
- GSK Investigational Site, Austin
- GSK Investigational Site, Bellaire
- og 4 flere
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07701993A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
- American Research Corporation, Austin
- Advanced Medical Trials, Georgetown
- American Research Corporation at The Texas Liver Institute, San Antonio
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 29. sep. 2026 · NCT07527910A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- American Research Corporation, Austin
- Pinnacle Clinical Research - Austin, Austin
- Methodist Dallas Medical Center, Dallas
- og 5 flere
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- IMA Clinical Research Austin, Austin
- American Research Corporation, Austin
- Pinnacle Clinical Research, Austin
- og 26 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Arlington
- Akero Clinical Study Site, Austin
- Akero Clinical Study Site, Austin
- og 28 flere
RekruttererFase 3
Alder 18 til 80 · Alle kjønn · Oppdatert 21. sep. 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Austin
- GSK Investigational Site, Austin
- GSK Investigational Site, Brownsville
- og 12 flere
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Pinnacle Clinical Research, Austin
- Bellaire Clinical Research, Bellaire
- South Texas Research Institute (STRI) - Brownsville, Brownsville
- og 14 flere
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Amarillo
- 89bio Clinical Study Site, Austin
- 89bio Clinical Study Site, Austin
- og 30 flere
RekruttererFase 3
Alder 18 til 80 · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Amarillo
- 89bio Clinical Study Site, Austin
- 89bio Clinical Study Site, Austin
- og 21 flere
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06419374Quantifying Hepatic Mitochondrial Fluxes in Humans
- Texas Diabetes Institute - University Health System, San Antonio
- University of Texas Health Science Center at San Antonio, San Antonio
RekruttererFase 4
Alder 18 til 80 · Alle kjønn · Oppdatert 17. aug. 2026 · NCT05305287A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Arlington
- GSK Investigational Site, Austin
- GSK Investigational Site, Dallas
- og 4 flere
RekruttererFase 2
Alder 18 til 70 · Alle kjønn · Oppdatert 3. aug. 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Arlington
- GSK Investigational Site, Austin
- GSK Investigational Site, Austin
- og 16 flere
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 27. jul. 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Austin
- GSK Investigational Site, Austin
- GSK Investigational Site, Austin
- og 10 flere
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 8. jul. 2026 · NCT06920043A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
- GSK Investigational Site, San Antonio
RekruttererFase 1
Alder 18 til 70 · Alle kjønn · Oppdatert 9. jun. 2026 · NCT07358546Evaluating the Pharmacokinetics and Safety of Miricorilant
- Site# 433, San Antonio
RekruttererFase 1
Alder 18 til 75 · Alle kjønn · Oppdatert 26. mai 2026 · NCT07553663Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population
- Methodist Dallas Medical Center, Dallas
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 13. mai 2026 · NCT06225193A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Pioneer Research Solutions, Houston
RekruttererFase 1/2Frivillige helsepersonell ønskes velkommen
Alder 18 til 75 · Alle kjønn · Oppdatert 16. apr. 2026 · NCT05648214NAFLD Clinical Care Pathway
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 14. nov. 2025 · NCT06671886Evaluation of Non-Invasive Tests for Metabolic Liver Disease
- First Surgical Hospital, Bellaire
- Endeavor Clinical Trials, San Antonio
RekruttererObservasjonsstudie
Alder 18 til 75 · Alle kjønn · Oppdatert 14. aug. 2025 · NCT07122700Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.